MGLL and ovarian cancer: Molecular modeling and preliminary structure-based hit optimization studies allowed the discovery of derivative 4, which showed an efficient reversible MAGL inhibition (IC50 = 6.1 μM) and a promising antiproliferative activity on breast and ovarian cancer cell lines (IC50 of 31–72 μM), thus representing a lead for the development of new and more potent reversible MAGL inhibitors.